Earnings Releases

Enliven Therapeutics, Inc. reported the first quarter ended March 31, 2026 results: net income $23.6 million.

“Enliven reported a net loss of $23.6 million for the first quarter of 2026”

Absci Corp reported first quarter ended March 31, 2026 results: revenue $0.2 million.

“Revenue was $0.2 million for the three months ended March 31, 2026, compared to $1.2 million for the three months ended March 31, 2025.”

VALVOLINE INC updated its second quarter ended March 31, 2026 guidance (raised).

“On May 7, 2026, Valvoline Inc. (“Valvoline”) issued a press release ("Earnings Release") announcing its financial results for the second quarter ended March 31, 2026.”

International Seaways, Inc. reported first quarter 2026 results: revenue $325 million, net income $286 million, EPS $5.75 per diluted share.

“spot earnings that increased an average of approximately $30,000 per day across the fleet and an increase in gains on vessel sales. Shipping revenues for the first quarter were $325 million, compared to $183 million for the first quarter of 2025. Consolidated TCE revenues (1) for the first quarter were $317 million, compared to $178 million for the first quarter of”

Coinbase Global, Inc. reported financial results for the quarter ended March 31, 2026.

“On May 7, 2026 , Coinbase Global, Inc. (the “Company”) published a presentation related to its financial results for the quarter ended March 31, 2026”

ACM Research, Inc. reported first quarter ended March 31, 2026 results: revenue $231,263, net income $17,307, EPS $0.24. Guidance reaffirmed.

“requirements across a broad and expanding global customer base.” Three Months Ended March 31, GAAP Non-GAAP(1) 2026 2025 2026 2025 (dollars in thousands, except EPS) Revenue $ 231,263 $ 172,347 $ 231,263 $ 172,347 Gross margin 46.4 % 47.9 % 46.5 % 48.2 % Income from operations $ 36,177 $ 25,777 $ 41,798 $ 35,594 Net income attributable to ACM Research, Inc. $”

Shattuck Labs, Inc. reported first quarter ended March 31, 2026 results: net income $14.8 million for the quarter ended March 31, 2026, or $0.13 per basic and diluted share, EPS $0.13 per basic and diluted share.

“Shattuck Labs Reports First Quarter 2026 Financial Results”

Tectonic Therapeutic, Inc. reported financial results for the first quarter ended March 31, 2026.

“On May 7, 2026, Tectonic Therapeutic, Inc. announced its financial results for the quarter ended March 31, 2026 and provided a general business update.”

Varex Imaging Corp reported third quarter of fiscal year 2026 results: revenue between $210 million and $225 million, EPS Non-GAAP net earnings per diluted share is expected to be between $0.15 and $0.30. Guidance initiated.

“Guidance for the third quarter of fiscal year 2026 is as follows: • Revenues are expected to be between $210 million and $225 million • Non-GAAP net earnings per diluted share is expected to be between $0.15 and $0.30”

Varex Imaging Corp reported second quarter fiscal year 2026 results: revenue $216 million, EPS GAAP net loss $0.19 per diluted share | Non-GAAP net income* $0.21 per diluted share. Guidance reaffirmed.

“CITY, May 7, 2026 – Varex Imaging Corporation (Nasdaq: VREX) today announced its unaudited financial results for the second quarter fiscal year 2026. Q2FY26 Summary • Revenues $216 million • GAAP gross margin 34% | Non-GAAP gross margin* 34% • GAAP operating margin 7% | Non-GAAP operating margin* 9% • GAAP net loss $0.19 per diluted share | Non-GAAP net income*”

Cars.com Inc. reported first quarter ended March 31, 2026 results: revenue $180.2 million, net income $5.0 million, EPS $0.08 per diluted share.

“and is incorporated herein by reference. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Cars.com Reports First Quarter 2026 Results • Revenue grew in line with guidance to $180.2 million, up 1% year-over-year • Net income increased to $5.0 million compared to net loss of ($2.0) million in the prior year • Adjusted EBITDA grew to $51.0 million, up 1%”

DXC Technology Co reported full fiscal year 2027 results: revenue in the range of $12.11 billion to $12.35 billion, EPS in the range of $2.40 to $2.90. Guidance initiated.

“Total revenue in the range of $12.11 billion to $12.35 billion, a decline of 5.0% to 3.0% year-over-year on an organic basis.”

DXC Technology Co reported First quarter fiscal year 2027 and full fiscal year 2027 results: revenue in the range of $2.97 billion to $3.00 billion, EPS ~$0.40. Guidance initiated.

“Total revenue in the range of $2.97 billion to $3.00 billion, a decline of 7.5% to 6.5% year-over-year on an organic basis.”

DXC Technology Co reported full fiscal year 2026 results: revenue $12.64 billion, EPS $0.10.

“Total revenue was $12.64 billion, down 1.8% year-over-year, down 4.8% on an organic basis.”

DXC Technology Co reported the fourth quarter and full year of fiscal 2026 ended March 31, 2026 results: revenue $3.13 billion, EPS $(0.84).

“forth by specific reference in such a filing. --- EX-99.1 (EX-99.1) --- DXC Technology Reports Fourth Quarter and Full Fiscal Year 2026 Results • Total revenue for Q4 FY26 of $3.13 billion, down 1.2% YoY, down 6.6% on an organic basis (1) • Q4 FY26 Bookings of $3.3 billion, book to bill ratio of 1.07x • Q4 FY26 EBIT margin of (1.2)%, and adjusted EBIT (2) margin of”

Entrada Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2026.

“On May 7, 2026, Entrada Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2026 and other corporate updates.”

Kinetik Holdings Inc. reported the quarter ended March 31, 2026 results: net income $5.1 million. Guidance reaffirmed.

“For the three months ended March 31, 2026, Kinetik reported net loss including noncontrolling interest of $5.1 million, Adjusted EBITDA 1 of $251.2 million, Distributable Cash Flow 1 of $180.8 million, and Free Cash Flow 1 of $101.4 million.”

Vistra Corp. updated its fiscal year 2026 guidance (reaffirmed).

“Reaffirmed 2026 Ongoing Operations Adjusted EBITDA 1 and Ongoing Operations Adjusted FCFbG 1 guidance ranges of $6.8 billion to $7.6 billion and $3.925 billion to $4.725 billion, respectively.”

Vistra Corp. reported quarter ended March 31, 2026 results: net income $1,029 million. Guidance reaffirmed.

“For the quarter ended March 31, 2026, Vistra reported Net Income of $1,029 million and Ongoing Operations Adjusted EBITDA 1 of $1,494 million.”

Once Upon a Farm, PBC reported Full year 2026 results: revenue $313 million to $323 million. Guidance raised.

“Raising 2026 net sales outlook to $313 million to $323 million”

Once Upon a Farm, PBC reported the first quarter ended March 31, 2026 results: revenue $72.7 million, net income $15.8 million.

“First Quarter 2026 Financial Highlights Compared to Prior Year Period • Net sales increased 43.7% to $72.7 million • Gross margin of 40.8% compared to 37.7% • Net loss of $15.8 million compared to a net loss of $19.5 million”

Cactus, Inc. reported first quarter ended March 31, 2026 results: revenue $388.3 million, net income $40.2 million, EPS diluted loss per Class A share of $0.70.

“1, 2026, Cactus closed on its previously announced acquisition of a majority interest in Baker Hughes' Surface Pressure Control business (“Cactus International”); • Revenue of $388.3 million and operating income of $49.5 million; • Net income of $40.2 million and diluted loss per Class A share of $0.70; • Adjusted net income (1) of $56.2 million and diluted earnings”

Black Diamond Therapeutics, Inc. reported first quarter ended March 31, 2026 results: net income $9.0 million.

“Net loss for the first quarter of 2026 was $9.0 million, as compared to net income of $56.5 million for the same period in 2025.”

Optimum Communications, Inc. reported the quarter ended March 31, 2026 results: revenue $2.07 billion, net income ($2,884.1) million, EPS ($6.10)/share on a diluted basis.

“structure, are the right foundation for creating durable long-term value for our customers, our employees, and our shareholders." First Quarter 2026 Overview • Total revenue of $2.07 billion in Q1 2026 (-4.0% year over year) • Residential revenue of $1.56 billion in Q1 2026 (-6.5% year over year) ◦ Residential average revenue per user (ARPU) (1) $132.32 (-1.2% year”

Korro Bio, Inc. reported first quarter ended March 31, 2026 results: net income $19.6 million.

“Korro’s net loss was $19.6 million for the three months ended March 31, 2026”

Bluejay Diagnostics, Inc. reported fiscal quarter ended March 31, 2026 results: net income approximately $1.9 million.

“As of March 31, 2026, Bluejay reported cash and cash equivalents of approximately $3.7 million. The Company reported a net loss of approximately $1.9 million for the first quarter of 2026, compared to approximately $1.9 million for the same period in 2025.”

Zai Lab Ltd reported the first quarter of 2026 results: revenue $99.6 million, net income Net loss was $51.0 million, EPS loss per ADS of $0.46.

“forth by specific reference in such filing. --- EX-99.1 (EX-99.1) --- Zai Lab Announces First Quarter 2026 Financial Results and Recent Corporate Updates – Total revenues of $99.6 million for the first quarter of 2026, reflecting anticipated first-quarter dynamics, including certain competitive impacts for ZEJULA and pricing adjustment related to NRDL renewal for”

Funko, Inc. reported 2026 Second Quarter results: revenue Net sales $195 million to $205 million, up 1% to 6% compared with Q2 2025. Guidance initiated.

“2026 Second Quarter Net sales $195 million to $205 million, up 1% to 6% compared with Q2 2025 Gross margin % ~42% to 44% Adjusted EBITDA* $5 million to $10 million”

Funko, Inc. reported 2026 Full Year results: revenue Net Sales flat to up 3% vs 2025. Guidance reaffirmed.

“Current Outlook 2026 Full Year Net Sales flat to up 3% vs 2025 Gross Margin % ~41% to 43% Adjusted EBITDA* $70 million to $80 million”

Funko, Inc. reported First Quarter 2026 results: revenue Net sales were $200.9 million, net income Net loss was $18.1 million, EPS $0.33 per share.

“Net sales were $200.9 million compared with $190.7 million • Gross profit was $88.8 million, equal to gross margin of 44.2%, compared with $76.9 million, equal to gross margin of 40.3% • SG&A expenses were $83.7 million compared with $84.8 million • Net loss was $18.1 million, or $0.33 per share, compared with $28.1 million, or $0.52 per share”

Edgewise Therapeutics, Inc. reported financial results for first quarter of 2026.

“Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the first quarter of 2026 and recent business highlights.”

Core Natural Resources, Inc. reported first quarter of 2026 results: revenue $1.1 billion, net income $21.0 million, EPS $0.41 per diluted share.

“Core Natural Resources, Inc. (NYSE: CNR) (“Core” or the “company”) reported net income of $21.0 million, or $0.41 per diluted share, in the first quarter of 2026. Additionally, Core reported adjusted EBITDA 1 of $179.9 million in the quarter. Revenues totaled $1.1 billion in Q1.”

Evergy, Inc. reported first quarter ended March 31, 2026 results: net income $151.5 million, EPS $0.64 per share. Guidance reaffirmed.

“Evergy, Inc. (NASDAQ: EVRG) today announced first quarter 2026 GAAP earnings of $151.5 million, or $0.64 per share”

Liberty Latin America Ltd. reported financial results for the three months ended March 31, 2026.

“Liberty Latin America Ltd. (“Liberty Latin America” or “LLA”) (NASDAQ: LILA and LILAK, OTC Link: LILAB) today announced its financial and operating results for the three months (“Q1”) ended March 31, 2026.”

Denali Therapeutics Inc. reported financial results for the first quarter ended March 31, 2026.

“On May 7, 2026, Denali Therapeutics Inc. (the "Company") issued a press release announcing its financial results for the first quarter ended March 31, 2026.”

Red Violet, Inc. reported first quarter ended March 31, 2026 results: revenue $25.8 million, net income $4.4 million, EPS $0.31 and $0.30 per basic and diluted share.

“red violet Announces First Quarter 2026 Financial Results Revenue Increases 17% to a Record $25.8 Million; Net Income Increases 28% to $4.4 Million”

Amneal Pharmaceuticals, Inc. reported first quarter ended March 31, 2026 results: revenue $723 million, net income $62 million, EPS $0.19. Guidance reaffirmed.

“AMNEAL REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS ‒ Q1 2026 Net Revenue of $723 million; GAAP Net Income of $62 million; Diluted Income per Share of $0.19 ‒”

Scholar Rock Holding Corp reported the quarter ended March 31, 2026 results: net income $105.5 million, EPS $0.83.

“Scholar Rock reported a net loss of $105.5 million, including stock-based compensation of $18.2 million, for the quarter ended March 31, 2026, compared to a net loss of $74.7 million, including stock-based compensation of $13.4 million, for the quarter ended March 31, 2025. Net loss per common share was $0.83 for the quarter ended March 31, 2026, compared to $0.67 per common share for the quarter ended March 31, 2025.”

i3 Verticals, Inc. reported six months ended March 31, 2026 results: revenue $110.2 million, net income $3.3 million, EPS $0.09.

“Revenue from continuing operations 1 for the six months ended March 31, 2026, was $110.2 million, an increase of 3.6% over the prior year's first six months.”

i3 Verticals, Inc. reported fiscal second quarter ended March 31, 2026 results: revenue $57.5 million, net income $2.2 million, EPS $0.07.

“Second quarter revenue from continuing operations 1 was $57.5 million, an increase of 6.2% over the prior year's second quarter.”

Blackstone Secured Lending Fund reported financial results for first quarter ended March 31, 2026.

“On May 7, 2026, Blackstone Secured Lending Fund issued a press release and detailed presentation announcing its financial results for the first quarter ended March 31, 2026.”

Camp4 Therapeutics Corp reported the first quarter ended March 31, 2026 results: net income Net loss for the quarter ended March 31, 2026 was $18.3 million, compared to $12.4 million for the quarter ended March 3.

“CAMP4 Therapeutics Corporation ("CAMP4") (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced financial results for the first quarter ended March 31, 2026, and provided recent corporate highlights.”

Arlo Technologies, Inc. reported first quarter ended March 29, 2026 results: revenue $150,382, net income $15 million, EPS $0.14.

“$6.4 million resulting in a 51% return. Page 1 Three Months Ended March 29, 2026 December 31, 2025 March 30, 2025 (In thousands, except percentage and per share data) Revenue $ 150,382 $ 141,297 $ 119,066 GAAP gross margin 48.3 % 46.4 % 44.3 % Non-GAAP gross margin (2) 50.1 % 47.8 % 45.5 % GAAP earnings (loss) per share - basic $ 0.14 $ 0.05 $ (0.01) Non-GAAP”

Nuveen Churchill Direct Lending Corp. reported financial results for first quarter ended March 31, 2026.

“NEW YORK, May 7, 2026 - Nuveen Churchill Direct Lending Corp. (NYSE: NCDL) (“NCDL” or the “Company”), a business development company externally managed by its investment adviser, Churchill DLC Advisor LLC (the “Adviser”), and by its sub-adviser, Churchill Asset Management LLC (“Churchill”), today reported financial results for the first quarter ended March 31, 2026.”

IN8BIO, INC. reported the first quarter ended March 31, 2026 results: net income a net loss of $5.1 million, or $0.26 per basic and diluted common share, EPS $0.26 per basic and diluted common share.

“The Company reported a net loss of $5.1 million, or $0.26 per basic and diluted common share, for the three months ended March 31, 2026, compared with a net loss of $5.6 million, or $2.16 per basic and diluted common share, for the comparable prior year period.”

Corsair Gaming, Inc. reported first quarter 2026 results: revenue $354.5 million, net income increased $23.4 million YoY, EPS $0.11 / $0.27 GAAP / Non-GAAP EPS.

“adjusted EBITDA margin. • GAAP diluted earnings per share increased 210% YoY to $0.11, while non-GAAP diluted earnings per share increased 145% YoY to $0.27. • Revenue of $354.5 million, above the midpoint of our guided range, reflecting strong growth in Gamer and Creator Peripherals, partially offset by softer demand in Gaming Components and Systems driven by”

BridgeBio Pharma, Inc. reported the first quarter ended March 31, 2026 results: revenue $194.5 million.

“except as expressly set forth by specific reference in such a filing. --- EX-99.1 (EX-99.1) --- BridgeBio Reports First Quarter 2026 Financial Results and Corporate Updates - $194.5 million in total first quarter revenues, comprised of $180.6 million of U.S. Attruby® net product revenue, with strong prescribing growth and patient persistence driving continued”

Beam Therapeutics Inc. reported financial results for quarter ended March 31, 2026.

“On May 7, 2026, the Company issued a press release announcing its financial results for the quarter ended March 31, 2026.”

BlackSky Technology Inc. reported the first quarter ended March 31, 2026 results: revenue $20.8 million, net income Net loss for the first quarter of 2026 was $29.7 million. Guidance raised.

“rapidly entered commercial operations in less than one week • Next Gen-3 satellite ready to be shipped Financial Results Revenues Total revenue for the first quarter of 2026 was $20.8 million, compared to $29.5 million in the first quarter of 2025. The difference reflects the benefit in the first quarter of 2025 of $9.0 million related to a program milestone of a new”

AerSale Corp reported the fiscal quarter ended March 31, 2026 results: revenue $70.6 million, net income $3.5 million, EPS $(0.07) per diluted share.

“by specific reference in such a filing. ​ --- EX-99.1 (EX-99.1) --- ​ Exhibit 99.1 ​ AerSale Reports First Quarter 2026 Results ​ First Quarter 2026 Highlights ● Revenue of $70.6 million versus $65.8 million in the prior year period ● Net loss of $3.5 million versus net loss of $5.3 million in the prior year period ● Adjusted net income 1 of $0.1 million versus”